The US Pharmaceutical Industry Outlook to 2016.pdf
《The US Pharmaceutical Industry Outlook to 2016.pdf》由会员分享,可在线阅读,更多相关《The US Pharmaceutical Industry Outlook to 2016.pdf(89页珍藏版)》请在三一文库上搜索。
1、1 This is a licensed product of AM Mindpower Solutions and should not be copied 2 This is a licensed product of AM Mindpower Solutions and should not be copied TABLE OF CONTENTS List of Figures . 5 List of Tables 7 1. The US Pharmaceutical Industry Introduction . 9 2. The US Pharmaceutical Market Si
2、ze, 2005-2010 . 10 3. Top 50 Pharmaceutical Drugs in the US. 11 4. The US Regulations Pertaining to the Pharmaceutical Industry . 16 General Overview . 16 Health Care Reform 17 Patent. 18 5. The US Pharmacy Distribution and Reimbursement System . 20 6. The US Pharmaceutical Market Segmentation . 21
3、6.1. By Generic and Branded Drugs, 2005-2010 . 21 6.1.1. Generic Drugs Competitive Landscape, 2011 22 6.2. By Prescribed and Over the Counter Drugs (OTC), 2005-2010 . 23 6.2.1. Prescribed Drugs Market Segmentation, 2006-2010 24 6.2.1.1. Top Therapeutic Classes in the US by Prescriptions Dispensed an
4、d Spending, 2006-201025 6.2.1.2. The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, 2005-201027 6.2.1.3. The US Prescription Drug Competitive Landscape, 2010 28 6.2.1.4. Top US Pharmacies by Total Prescription Revenues, 2011 30 6.2.2. OTC Drugs Market Segmentation, 2007-2010
5、 . 31 6.3. The US Biologics/Biopharmaceutical Market 33 6.3.1. The US Biologics/Biopharmaceutical Market Size By Value, 2006-2011. 33 6.3.2. Top Selling Biologic Drugs, 2010 34 3 This is a licensed product of AM Mindpower Solutions and should not be copied 6.3.3. Top US Biopharmaceutical Companies M
6、arket Share, 2011 . 35 6.3.4. Biologic Drugs Future Projections, 2012-2016 37 6.4. The US Specialty Drugs Market . 38 7. The US Pharmaceutical Industry Trends and Developments . 40 Rising Expenditure on Biopharmaceutical Research and Development 40 Expanding Generic Drug Market 41 Rising Prescriptio
7、n Drug Prices 43 Rise in Shortage of Drugs . 44 Rising M Cause: Rising prices of branded drugs which are on the verge of patent expiry to increase their return along with surging R Negative; Cause: Cost cutting pressure, high competition and decreased R Cause: The US has highly developed chemical an
8、d technology industry and is the home to the largest scientific and research base with the presence of large number of scientists and abundant resource. Effect: Expected to witness an incline in the number of companies setting their R Negative; Cause: Efforts for expanding the insurance coverage, pr
9、ovision of discounts to specified insurance beneficiaries and retired individuals and efforts to control drug prices Positive Effect: Increased benefits for customers covered under the program with the access to reduced/discounted medicine leading to an increase in the demand for discounted drugs an
10、d medicine Negative Effect: Increased pressure on pharmaceutical companies as the profit margins will be hit along with the rising cost Shortage of Drugs Negative; Cause: Problems at the manufacturing facility, delays in production and/or shipping and shortage of active pharmaceutical ingredients ar
11、e leading to a shortage of drugs especially of 53 This is a licensed product of AM Mindpower Solutions and should not be copied oncology drugs, antibiotics and electrolyte/nutrition drugs, Effect: Expected to poise a major cause of concern to the health care providers, their patients and the general
12、 healthcare community; illegal price gouging and imports of drugs from other countries Expansion into Emerging Markets Positive; Cause: Competition for more market coverage and Tap the opportunities in emerging market Effect: Expected to expand consumer base with cheap labour resources leading to hi
13、gher growth opportunities for the pharmaceutical companies Rising Chronic Diseases Positive; Cause: Inclined Lifestyle towards junk food, increasing pollution and adulteration in the food along with increasing and aging population will lead to the rise in chronic disease in the near future Effect: E
14、xpected to increase the number of new drugs being produced in order to curb the impact of these disease with increased consumer base Source: AM Mindpower Note: Shaded region represents the degree of impact on the market 11. MAJOR PHARMACEUTICAL COMPANY PROFILES 11.1. PFIZER INC. COMPANY OVERVIEW Inc
15、orporated in 1942, Pfizer is the largest research -based pharmaceutical company in the world, and in the US. The companys diverse portfolio includes human and animal biologics and small molecule medicines and vaccines, nutritional products and several globally renowned healthcare products. The compa
16、ny operates in 2 segments: Biopharmaceutical: Includes primary care, specialty care, established products, emerging markets and oncology customerfocused units which offers products that avert and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infec
17、tious and respiratory diseases and others. The key products in this segment include Lipitor, Zoloft, Viagra, Zyvox, and others. 54 This is a licensed product of AM Mindpower Solutions and should not be copied Diversified: It includes: Animal health products that avert and treat diseases in livestock
18、 and companion animals. Some products under this segment include Draxxin, Excede, Naxcel/Excenel, RespiSure/Stellamune, Dectomax, Rimadyl Consumer Healthcare products that include OTC healthcare products such as pain management therapies, cough/cold/allergy remedies, dietary supplements, hemorrhoida
19、l care and other personal care items; Nutrition products such as infant and toddler formula products; and Capsugel, which represents our hard capsules business Table 23: Pfizers Product Patent Expiration Year Pfizer Drug US. Basic Product Patent Expiration Year Aricept 2010 Lipitor 2011 BeneFIX 2011
20、 Xalatan 2011 Geodon 2012 Viagra 2012 Detrol 2012 Celebrex 2014 Prempro Z 2015 Zyvox 2015 Lyrica 2018 Chantix 2020 Sutent 2021 Source: Company Reports 55 This is a licensed product of AM Mindpower Solutions and should not be copied BUSINESS STRATEGIES Growth Through Mergers and Acquisitions Pfizer f
21、ocuses on achieving growth and portfolio diversity through acquisitions. The company acquired Wyeth, a pharmaceutical company, for approximately USD 68 billion on October 15, 2009. On October 2010, the Company announced acquisition of 92.5% share of King Pharmaceuticals, Inc., a diversified specialt
22、y pharmaceutical discovery and clinical development company, for USD 3.6 billion in cash. Retain Sales of Blockbuster Drugs whose Patents have Expired Pfizer is working hard on retaining the sales of blockbuster drugs which have lost their patent protection and are now under the threat of generic dr
23、ugs. Lipitor, the highest selling drug of Pfizer lost its patent protection on November 30, 2010. The company is offering discounts and incentives to patients, physicians, insurers and companies for prescribing their drugs. Pfizer looks to retain a good portion of sales through these campaigns. The
24、company has spent millions of dollars in marketing and promoting Lipitor. Achieve Operational Efficiency In early 2011, the company stated that it will continue to evaluate their global research and development function and will accelerate their current strategies to develop innovation and overall p
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- The US Pharmaceutical Industry Outlook to 2016
链接地址:https://www.31doc.com/p-3801076.html